LU93315I2 - Procédé de traitement de la sclérose multiple - daclizumab - Google Patents

Procédé de traitement de la sclérose multiple - daclizumab Download PDF

Info

Publication number
LU93315I2
LU93315I2 LU93315C LU93315C LU93315I2 LU 93315 I2 LU93315 I2 LU 93315I2 LU 93315 C LU93315 C LU 93315C LU 93315 C LU93315 C LU 93315C LU 93315 I2 LU93315 I2 LU 93315I2
Authority
LU
Luxembourg
Prior art keywords
daclizumab
multiple sclerosis
treating multiple
treating
sclerosis
Prior art date
Application number
LU93315C
Other languages
English (en)
French (fr)
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93315(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of LU93315I2 publication Critical patent/LU93315I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
LU93315C 2002-06-28 2016-11-17 Procédé de traitement de la sclérose multiple - daclizumab LU93315I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39302102P 2002-06-28 2002-06-28
PCT/US2002/038290 WO2004002500A1 (en) 2002-06-28 2002-11-27 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
PCT/US2003/020428 WO2004002421A2 (en) 2002-06-28 2003-06-27 Method for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
LU93315I2 true LU93315I2 (fr) 2017-01-26

Family

ID=30000962

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93315C LU93315I2 (fr) 2002-06-28 2016-11-17 Procédé de traitement de la sclérose multiple - daclizumab

Country Status (15)

Country Link
US (11) US7575742B2 (OSRAM)
EP (3) EP3269377A1 (OSRAM)
JP (8) JP2005535636A (OSRAM)
AU (3) AU2002368055B2 (OSRAM)
CA (3) CA2490804C (OSRAM)
CY (2) CY2016043I2 (OSRAM)
DK (2) DK2314627T3 (OSRAM)
ES (2) ES2474718T3 (OSRAM)
HK (1) HK1249850A1 (OSRAM)
HU (2) HUE036677T2 (OSRAM)
IL (2) IL165973A (OSRAM)
LU (1) LU93315I2 (OSRAM)
PT (2) PT1539200E (OSRAM)
SI (2) SI1539200T1 (OSRAM)
WO (2) WO2004002500A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100884973B1 (ko) * 2001-04-26 2009-02-23 모션 테크놀로지즈 엘엘씨 연속 가변 변속기의 속력비를 조절하는 장치 및 방법
AU2002368055B2 (en) * 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
US20060134750A1 (en) * 2004-03-10 2006-06-22 Pepgen Corporation Method of treatment using interferon-tau
MX2007008220A (es) 2005-01-12 2007-08-17 Biogen Idec Inc Metodo para liberar interferon-beta.
WO2006089066A1 (en) * 2005-02-15 2006-08-24 Neuromolecular Pharmaceuticals, Inc. Combinations therapy for treatment of demyelinating conditions
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
US20100055098A1 (en) * 2008-08-28 2010-03-04 Facet Biotech Corporation Method for treating multiple sclerosis patients with anti-il2r antibodies
WO2010045265A1 (en) * 2008-10-13 2010-04-22 Biovista, Inc. Compositions and methods for treating multiple sclerosis
WO2010068923A2 (en) * 2008-12-12 2010-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents that selectively inhibit cd25 on dendritic cells or t cells and their use
CA2771335A1 (en) * 2009-08-31 2011-03-03 Abbott Biotherapeutics Corp. Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
CN102939305B (zh) * 2010-04-08 2016-08-17 Jn生物科学有限责任公司 对cd122的抗体
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
ES2778053T3 (es) 2011-01-18 2020-08-07 Bioniz Llc Composiciones para modular la actividad de la citocina gamma-c
WO2013022972A1 (en) 2011-08-08 2013-02-14 Abbott Biotherapeutics Corporation Methods of treating progressive forms of multiple sclerosis
KR102654684B1 (ko) 2015-10-09 2024-04-04 바이오니즈 테라퓨틱스, 아이엔씨. 감마-ｃ-사이토카인 활성의 조정
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
DE102017104088A1 (de) * 2017-02-28 2018-08-30 L&O Hunting Group GmbH Integralschalldämpfer für einen Gewehrlauf
US12030936B2 (en) 2019-05-03 2024-07-09 Bioniz Therapeutics, Inc. Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
CN114449941A (zh) * 2019-08-07 2022-05-06 艾迪菲斯健康有限公司 心血管疾病的治疗和预防

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4819150A (en) 1985-04-05 1989-04-04 Unisys Corporation Array for simulating computer functions for large computer systems
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5336489A (en) 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5695927A (en) 1988-03-31 1997-12-09 The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology Monoclonal antibodies specific for HIV and the hybridomas for production thereof
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
US5152980A (en) 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5620686A (en) 1990-09-28 1997-04-15 British Technology Group Limited Antigen-antibody conjugates
US5840496A (en) * 1990-10-09 1998-11-24 Chiron Corporation Method for diagnosing endometrial cancer
FR2672291A1 (fr) 1991-01-31 1992-08-07 Inst Nat Sante Rech Med Composition d'anticorps diriges contre le recepteur de l'interleukine-2 humaine ou animale.
GB9115010D0 (en) 1991-07-11 1991-08-28 Wellcome Found Antibody
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5571507A (en) 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
PT699077E (pt) 1993-05-07 2002-04-29 Bio Merieux Inc Complexo imunogenico de hiv
CA2159366A1 (en) 1993-08-27 1995-03-02 Michael R. Perry Mechanical gas flushing system
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US6833135B1 (en) * 1997-08-06 2004-12-21 Laboratorio Medinfar Produtos Farmaceuticos, Lda. DNA integration into “Mycobacterium spp.” genome by trans-complementation using a site-specific integration system
WO2000025816A1 (en) 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
AU2001248839A1 (en) 2000-04-25 2001-11-07 Tomoaki Hoshino Remedies for interstitial pneumonia, method of constructing animal model of this disease and screening method with the use of the same
HUP0400986A3 (en) * 2001-04-06 2012-09-28 Univ Bristol Use of cd25 binding molecules in steroid-resistant patients
AU2002368055B2 (en) * 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production

Also Published As

Publication number Publication date
ES2474718T3 (es) 2014-07-09
US20130095069A1 (en) 2013-04-18
US20080038275A1 (en) 2008-02-14
IL241920A0 (en) 2015-11-30
WO2004002500A1 (en) 2004-01-08
US8636997B2 (en) 2014-01-28
PT2314627T (pt) 2017-08-29
US8454965B2 (en) 2013-06-04
AU2003247813A1 (en) 2004-01-19
SI2314627T1 (sl) 2017-10-30
PT1539200E (pt) 2014-08-25
EP2314627A2 (en) 2011-04-27
US20130017152A1 (en) 2013-01-17
CY2016043I1 (el) 2017-04-05
EP3269377A1 (en) 2018-01-17
JP5905534B2 (ja) 2016-04-20
JP2016145220A (ja) 2016-08-12
JP2014221813A (ja) 2014-11-27
DK2314627T3 (en) 2017-10-23
EP1539200A2 (en) 2005-06-15
HK1249850A1 (en) 2018-11-16
JP2011157378A (ja) 2011-08-18
HUS1600050I1 (hu) 2017-06-28
CA2490804A1 (en) 2004-01-08
US20040109859A1 (en) 2004-06-10
EP1539200A4 (en) 2007-11-07
CY2016043I2 (el) 2017-04-05
EP2314627B1 (en) 2017-07-26
US8298525B2 (en) 2012-10-30
AU2003247813C1 (en) 2010-07-22
CA2844639A1 (en) 2004-01-08
US7258859B2 (en) 2007-08-21
WO2004002421A2 (en) 2004-01-08
WO2004002421A3 (en) 2004-09-02
HK1074769A1 (en) 2005-11-25
JP2006508039A (ja) 2006-03-09
SI1539200T1 (sl) 2014-09-30
US20150010477A1 (en) 2015-01-08
AU2008212004A1 (en) 2008-09-25
CA2490804C (en) 2016-12-06
IL165973A (en) 2015-10-29
JP2013032372A (ja) 2013-02-14
CA2490186A1 (en) 2004-01-08
AU2002368055B2 (en) 2008-09-18
US20050249704A1 (en) 2005-11-10
EP2314627A3 (en) 2011-05-11
JP2013139478A (ja) 2013-07-18
US20170190779A1 (en) 2017-07-06
AU2003247813B2 (en) 2008-06-05
ES2637011T3 (es) 2017-10-10
HUE036677T2 (hu) 2018-07-30
DK1539200T3 (da) 2014-06-30
IL165973A0 (en) 2006-01-15
US20090175823A1 (en) 2009-07-09
AU2008212004B2 (en) 2010-10-21
US20190002575A1 (en) 2019-01-03
JP2010132660A (ja) 2010-06-17
CY1119389T1 (el) 2018-02-14
EP1539200B1 (en) 2014-05-28
JP2005535636A (ja) 2005-11-24
US20150337044A1 (en) 2015-11-26
AU2002368055A1 (en) 2004-01-19
CA2490186C (en) 2014-04-15
US20180237532A1 (en) 2018-08-23
US7575742B2 (en) 2009-08-18

Similar Documents

Publication Publication Date Title
LU93315I2 (fr) Procédé de traitement de la sclérose multiple - daclizumab
EP1655036A4 (en) METHOD OF TREATING ONCOLOGICAL DISEASES
EP1545700A4 (en) METHOD FOR TREATING DAMAGE TO THE CENTRAL NERVOUS SYSTEM
IL175818A0 (en) Method for treating adamts-5- associated disease
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
FR2814945B1 (fr) Procede de traitement de la canitie
FI20020479A0 (fi) Pintakäsittelyprosessi
EP1489506A4 (en) DECENTRALIZED PROCESSING SYSTEM, JOB-DECENTRALIZED PROCESSING PROCESS AND PROGRAM
FI20040011L (fi) Menetelmä pintojen käsittelemiseksi
EP1492902A4 (en) Composition and process for the treatment of metal surfaces
FI20020817A7 (fi) Pintakäsittelyprosessi
FI20012170L (fi) Menetelmä lauhteiden käsittelemiseksi
FI20020942A0 (fi) Menetelmä tärkkelyksen käsittelemiseksi
FI20022150A7 (fi) Menetelmä kuonan käsittelemiseksi
FI20030380L (fi) Menetelmä prosessin säätämiseksi
FI20030735A0 (fi) Menetelmä ja laite veden käsittelemiseksi
BR0312187B1 (pt) método para o tratamento de sementes
FI20030497A0 (fi) Menetelmä jätehapon käsittelemiseksi
EP1599193A4 (en) METHOD FOR THE TREATMENT OF HYPOTHYREOIDISM
FI20030736A0 (fi) Menetelmä ja laite veden käsittelemiseksi
FI20020849A0 (fi) Menetelmä tekstiilin käsittelyyn
FI20030381L (fi) Menetelmä prosessin säätämiseksi
FR2853309B1 (fr) Procede et installation de traitement de dejections animales
ITMI20020809A1 (it) Metodo per la selezione di composti utili nel trattamento della coreadi huntington
FI20031151L (fi) Menetelmä jätteen käsittelyyn